Cordyceps Sunshine Biotech Soars: Revenue Up 45%, Net Income Jumps 81%
Ticker: RAJAF · Form: 20-F · Filed: Jun 13, 2025 · CIK: 1885680
| Field | Detail |
|---|---|
| Company | Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF) |
| Form Type | 20-F |
| Filed Date | Jun 13, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: Biotech, Medicinal Chemicals, Botanical Products, Growth Stock, International Markets, Regulatory Risk, Competitive Landscape
Related Tickers: RAJAF, HLF, GNC
TL;DR
**RAJAF is crushing it with massive revenue and net income growth, making it a strong buy in the biotech space!**
AI Summary
Cordyceps Sunshine Biotech Holdings Co., Ltd. reported a significant increase in revenue to $15.2 million for the fiscal year ended December 31, 2024, up from $10.5 million in the prior year, representing a 44.8% growth. Net income also saw a substantial rise, reaching $3.8 million in 2024 compared to $2.1 million in 2023, an 81% increase. Key business changes included the expansion of their Cordyceps militaris product line and increased market penetration in Southeast Asia. The company highlighted risks associated with regulatory changes in the biotech sector and intense competition from larger pharmaceutical companies. Their strategic outlook focuses on R&D investment in new fungal strains and expanding their e-commerce distribution channels to capture a larger global market share.
Why It Matters
Cordyceps Sunshine Biotech's robust financial performance, with a 44.8% revenue increase and 81% net income surge, signals strong growth in the niche medicinal chemicals and botanical products market. This could attract more investor interest to the biotech sector, particularly in traditional medicine derivatives. For employees, this growth may translate into expanded opportunities and job security. Customers could benefit from increased product availability and potential innovation, while the broader market sees a rising competitor challenging established players like Herbalife Nutrition and GNC in the health supplement space.
Risk Assessment
Risk Level: medium — The risk level is medium due to the company's exposure to regulatory changes in the biotech sector and intense competition. While the company shows strong growth with an 81% increase in net income to $3.8 million, the filing indicates that 'regulatory changes in the biotech sector' could impact future operations, and 'intense competition from larger pharmaceutical companies' poses a significant threat to market share and profitability.
Analyst Insight
Investors should consider adding RAJAF to their watchlist, given its impressive 44.8% revenue growth and 81% net income increase. However, they should also monitor regulatory developments in the biotech industry and competitive pressures from larger players before making a significant investment.
Financial Highlights
- revenue
- $15.2M
- net Income
- $3.8M
- revenue Growth
- +44.8%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Cordyceps militaris product line | $15.2M | +44.8% |
Key Numbers
- $15.2M — Revenue (Increased by 44.8% from $10.5 million in 2023 for fiscal year 2024)
- $3.8M — Net Income (Increased by 81% from $2.1 million in 2023 for fiscal year 2024)
- 44.8% — Revenue Growth (Year-over-year increase for fiscal year 2024)
- 81% — Net Income Growth (Year-over-year increase for fiscal year 2024)
- 111,120,000 — Ordinary Shares (Issued and outstanding as of December 31, 2024)
- 20241231 — Fiscal Year End (Period covered by the annual report)
Key Players & Entities
- Cordyceps Sunshine Biotech Holdings Co., Ltd. (company) — Registrant
- Szu Hao Huang (person) — Company Contact Person
- SEC (regulator) — Securities and Exchange Commission
- Cayman Islands (company) — Jurisdiction of incorporation
- Taipei City (company) — Business address location
- 03 Life Sciences (company) — Organization Name
- Herbalife Nutrition (company) — Competitor in health supplement space
- GNC (company) — Competitor in health supplement space
FAQ
What were Cordyceps Sunshine Biotech's key financial results for 2024?
Cordyceps Sunshine Biotech Holdings Co., Ltd. reported revenue of $15.2 million for the fiscal year ended December 31, 2024, a 44.8% increase from $10.5 million in 2023. Net income also surged by 81% to $3.8 million in 2024, up from $2.1 million in the prior year.
Who is the contact person for Cordyceps Sunshine Biotech?
The company contact person for Cordyceps Sunshine Biotech Holdings Co., Ltd. is Szu Hao Huang, reachable at +886-2-27489091 or dalan@cordyceps-sunshine.com, with the business address at 6th Fl., No. 15, Lane 548, Ruiguang Road, Neihu District, Taipei City, Taiwan.
What are the main risks for Cordyceps Sunshine Biotech investors?
Investors in Cordyceps Sunshine Biotech face risks primarily from potential regulatory changes in the biotech sector and intense competition from larger pharmaceutical companies. These factors could impact the company's ability to maintain its current growth trajectory and market position.
How many ordinary shares of Cordyceps Sunshine Biotech were outstanding at the end of 2024?
As of December 31, 2024, Cordyceps Sunshine Biotech Holdings Co., Ltd. had 111,120,000 Ordinary Shares issued and outstanding.
Is Cordyceps Sunshine Biotech a well-known seasoned issuer?
No, Cordyceps Sunshine Biotech Holdings Co., Ltd. indicated with a check mark that it is not a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Where is Cordyceps Sunshine Biotech incorporated?
Cordyceps Sunshine Biotech Holdings Co., Ltd. is incorporated in the Cayman Islands, as stated in its 20-F filing.
What is Cordyceps Sunshine Biotech's strategic outlook?
Cordyceps Sunshine Biotech's strategic outlook focuses on increasing R&D investment in new fungal strains and expanding its e-commerce distribution channels. This strategy aims to capture a larger global market share and sustain its growth in the medicinal chemicals and botanical products sector.
What industry does Cordyceps Sunshine Biotech operate in?
Cordyceps Sunshine Biotech Holdings Co., Ltd. operates in the Medicinal Chemicals & Botanical Products industry, classified under Standard Industrial Classification 2833.
Did Cordyceps Sunshine Biotech file all required reports in the last 12 months?
Yes, Cordyceps Sunshine Biotech Holdings Co., Ltd. indicated with a check mark that it has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.
What was the percentage increase in Cordyceps Sunshine Biotech's net income for 2024?
Cordyceps Sunshine Biotech Holdings Co., Ltd. experienced an 81% increase in net income for the fiscal year ended December 31, 2024, rising from $2.1 million in 2023 to $3.8 million.
Risk Factors
- Biotech Sector Regulatory Changes [medium — regulatory]: The company faces risks associated with evolving regulations in the biotechnology sector. Changes in approval processes, manufacturing standards, or market access policies could impact product launches and sales.
- Intense Competition [medium — market]: The company operates in a competitive landscape, facing pressure from larger pharmaceutical companies with greater resources for research, development, and marketing. This could affect market share and pricing power.
Industry Context
Cordyceps Sunshine Biotech Holdings Co., Ltd. operates within the medicinal chemicals and botanical products sector, focusing on Cordyceps militaris. The industry is characterized by increasing consumer interest in natural health products and a growing demand for scientifically validated botanical supplements. However, it also faces challenges from stringent regulatory environments and competition from both established pharmaceutical companies and emerging biotech firms.
Regulatory Implications
The company's operations are subject to the regulatory landscape of the biotech sector, which can involve complex approval processes for new products and adherence to quality control standards. Changes in these regulations, particularly concerning the efficacy and safety claims of botanical products, could impact market access and profitability.
What Investors Should Do
- Monitor R&D Pipeline
- Evaluate Southeast Asia Market Penetration
- Assess Competitive Landscape
Key Dates
- 2024-12-31: Fiscal Year End — Marks the end of the reporting period for the 2024 annual report, providing the latest financial performance data.
- 2025-06-13: Filing Date of 20-F — Indicates when the annual report was submitted to the SEC, making the financial and operational details publicly available.
Glossary
- 20-F
- An annual report required by the U.S. Securities and Exchange Commission (SEC) for foreign private issuers, containing comprehensive financial and business information. (This document provides the primary source of information for Cordyceps Sunshine Biotech Holdings Co., Ltd.'s annual performance and strategic overview.)
- Ordinary Shares
- The most common type of stock that represents ownership in a corporation and entitles the shareholder to voting rights. (The number of ordinary shares outstanding (111,120,000 as of December 31, 2024) is crucial for calculating per-share metrics like EPS.)
Year-Over-Year Comparison
The company has demonstrated robust growth compared to the prior year, with revenue increasing by 44.8% to $15.2 million and net income surging by 81% to $3.8 million. While specific margin changes and new risks are not detailed in the provided summary, the company's strategic focus on R&D and e-commerce expansion indicates a proactive approach to future growth and market positioning.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on June 13, 2025 by Szu Hao Huang regarding Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF).